Celsion is a clinical stage biotechnology company focused on developing a portfolio of treatments including DNA-based immunotherapies, vaccines and chemotherapies. Co.'s product pipeline includes GEN-1, a DNA-based immunotherapy for ovarian cancer treatment and ThermoDox®, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is under investigator-sponsored development for several cancer indications. Co. has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines and other anti-cancer DNA or RNA therapies. Both are synthetic, non-viral vectors with demonstrated capability in nucleic acid cellular transfection. The CLSN stock yearly return is shown above.
The yearly return on the CLSN stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the CLSN annual return calculation with any dividends reinvested as applicable (on ex-dates).
|